MIRD Pamphlet No. 19: Absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney

Journal of Nuclear Medicine

Volumn 44, Issue 7, 2003, Pages 1113-1147

  Bouchet, Lionel G ^a,b   Bolch, Wesley E ^a,b   Blanco, H Pablo ^a   Wessels, Barry W ^c   Siegel, Jeffry A ^d   Rajon, Didier A ^a   Clairand, Isabelle ^e   Sgouros, George ^f  

^a UNIVERSITY OF FLORIDA   (United States)

^b University of Florida   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Nuclear Physics Enterprises   (United States)

^e INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^f DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Kidney dosimetry; Mird schema; Pediatrics; Suborgan dosimetry

Indexed keywords

RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; YTTRIUM 90; DIAGNOSTIC AGENT;

ARTICLE; ELECTRON; ENERGY ABSORPTION; GLOMERULUS FILTRATION RATE; IMAGE ANALYSIS; KIDNEY CORTEX; KIDNEY PAPILLA; KIDNEY PARENCHYMA; KIDNEY PELVIS; MICRODOSIMETRY; PHOTON; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; AGING; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; BODY BURDEN; COMPARATIVE STUDY; COMPUTER SIMULATION; EVALUATION; HUMAN; KIDNEY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PHYSIOLOGY; RADIATION DOSE; RADIOMETRY; SENSITIVITY AND SPECIFICITY; STANDARD; TISSUE DISTRIBUTION;

AGING; BODY BURDEN; COMPUTER SIMULATION; HUMANS; KIDNEY; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 0042279207     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. McAfee JG. Problems in evaluating the radiation dose for radionuclides excreted by the kidneys. In: Cloutier RJ, Edwards CL, Snyder WS, eds Medical Radionuclides: Radiation Dose and Effects Oak Ridge, TN: U.S. Atomic Energy Commission, 1969:271-294
2. 99mTc-stannous dimercaptosuccinate in the rat by frozen section autoradiography the efficiency and resolution of technetium-99m. Radiat Res. 1977;69:475-488
3. Bonnin F, Petegnief Y, Petiet A, Stievenart JL, Colas-Linhart N, Bok B Tissular kinetics of radiopharmaceuticals (Rph) in the rat kidney using a radioimager (Ri) [abstract]. J Nucl Med. 1998;39(suppl):185P.
4. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997;80:2591-2610
5. Flynn A, Pedley R, Green A, et al. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry. Radiat Res 2003;159:182-189.
6. 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm. 1999;14:381-395.
7. Cristy M, Eckerman KF. Specific Absorbed Fractions of Energy at Various Ages from Internal Photon Sources ORNL/TM-8381/Vols. I-VII. Oak Ridge, TN. Oak Ridge National Laboratory; 1987.
8. Bolch WE, Bouchet LG, Robertson JS, et al. MIRD Pamphlet No. 17: the dosimetry of nonuniform activity distributions - radionuclide S values at the voxel level. J Nucl Med. 1999;40:11S-36S.
9. Marieb EN. Human Anatomy and Physiology. 5th ed. Menlo Park, CA: Benjamin Cummings Science Publishers; 1998.
10. Snyder WS, Ford MR, Warner GG. Fisher HL Jr. Estimates of Absorbed Fractions for Monoenergetic Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom. MIRD Pamphlet No. 5. New York, NY Society of Nuclear Medicine; 1969
11. ICRP Report an the Task Group on Reference Man. ICRP Publication 23 Oxford, U.K.: International Commission on Radiological Protection; 1975.
12. Snyder WS, Ford MR, Warner GG. Estimates of Specific Absorbed Fractions for Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom MIRD Pamphlet No 5, revised. New York, NY. Society of Nuclear Medicine; 1978
13. Snyder WS, Ford MR, Warner GG, Watson SB. "S," Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet No 11. New York, NY: Society of Nuclear Medicine; 1975
14. Cristy M. Mathematical Phantomy Representing Children of Various Ages for Use in Estimates of Internal Dose. ORNL/NUREG/TM-367, Oak Ridge, TN: Oak Ridge National Laboratory; 1980
15. Nelson WR, Hirayama RH, Roger DWO. The EGS4 Code System. SLAC-265. Stanford, CA: Stanford Linear Accelerator Center; 1985.
16. Ford RL, Nelson WR The EGS Code System: Computer Programs for Monte Carlo Simulation of Electromagnetic Cascade Shower. SLAC-210. Stanford, CA: Stanford Linear Accelerator Center; 1978.
17. Bouchet LG, Bolch WE, Weber DA, Atkins HL, Posten JW Sr. MIRD Pamphlet No. 15. radionuclide S values in a revised dosimetric model of the adult head and brain J Nucl Med. 1999;40:62S-101S.
18. Eckerman KF, Weslfall RJ, Ryman JC, Cristy M Availability of nuclear decay data in electronic form, including beta spectra not previously published. Health Phys 1994;67:338-345.
19. Eckerman KF, Westfall RJ, Ryman JC, Cristy M Nuclear Decay Data Files of the Dosimetry Research Group. ORNL/TM-12350 Oak Ridge. TN: Oak Ridge National Laboratory; 1993.
20. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122.
21. Kunkler PB, Farr RF, Luxton RW The limit of renal tolerance to x-rays. Br J Radiol. 1952;25:190-201
22. Luxton RW. Radiation nephritis, a long-term study of 54 patients Lancet. 1961;72:1221-1226.
23. Luxton RW. Radiation nephritis Q J Med. 1961;22:215-242.
24. Luxton RW, Kunkler PB. Radiation nephritis. Acta Radiol Ther Phys Biol. 1964;2:169-174
25. Hoopes PJ, Gillette EL, Benjamin SA. The pathogenesis of radiation nephropathy in the dog. Radiat Res 1985;104:406-419.
26. Hoopes PJ, Gillette EL, Cloran JA, Benjamin SA. Radiation nephropathy in the dog. Br J Cancer Suppl. 1986;7:273-276.
27. Stephens LC, Robbins ME, Johnston DA, et al. Radiation nephropathy in the rhesus monkey: morphometric analysis of glomerular and tubular alterations. Int J Radiat Oncol Biol Phys. 1995;31:865-873.
28. Robbins MEC, Bonsib SM Radiation nephropathy: a review. Scanning Microsc. 1995;9:535-560
29. Stewart FA, Lebesque JV, Hart AA Progressive development of radiation damage in mouse kidneys and the consequences for reirradiation tolerance. Int J Radiat Biol Relat Stud Phys Chem Med. 1988;53:405-415.
30. Stewart FA, Luts A, Lebesque IV The lack of long-term recovery and reirradiation tolerance in the mouse kidney. Int J Radiat Biol. 1989;56:449-462.
31. Stewart FA, Oussoren Y. Re-irradiation of mouse kidneys: a comparison of re-treatment tolerance after single and fractionated partial tolerance doses. Int J Radiat Biol 1990;58:531-544.
32. Lo YL, Kutcher GJ, Ling CC. Volume effect on the radiation injury to the rat kidney [abstract]. Int J Radiat Oncol Biol Phys. 1996;36(suppl):383.
33. Mohan R, Mageras GS, Baldwin B, et al Clinically relevant optimization of 3-D conformal treatments. Med Phys 1992;19:933-944.
34. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function Int J Radiat Oncol Biol Phys. 1991;21:123-135.
35. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 1985;8:S13-S19
36. Olsen DR, Kambestad BK, Kristoffersen DT. Calculation of radiation induced complication probabilities for brain, liver and kidney, and the use of a reliability model to estimate critical volume fractions. Br J Radiol. 1994;67:1218-1225.
37. Yorke ED, Kutcher GJ, Jackson A, Ling CC. Probability of radiation-induced complications in normal-tissues with parallel architecture under conditions of uniform whole or partial organ irradiation. Radiother Oncol. 1993;26:226-237.
38. Knox SJ, Meredith RF. Clinical radioimmunotherapy Semin Radiat Oncol. 2000;10:73-93.
39. Fowler JF Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1990;18:1261-1269
40. Langmuir VK, Fowler JF, Knox SJ, Wessels BW, Sutherland RM, Wong JYC. Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med Phys. 1993;20:601-610.
41. Dale RG Dose-rate effects in targeted radiotherapy. Phys Med Biol. 1996;41: 1871-1884.
42. ICRU. Absorbed Dose Specification in Nuclear Medicine. Report 67 Bethesda, MD: International Commission on Radiation Units and Measurements; 2002.
43. Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RH. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab′ fragments Br J Cancer. 1999;81:972-980.
44. 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med 2000;41:952-958.
45. Boerman OC, Oyen WJ, Corstens FH Between the Scylla and Charybdis of peptide radionuclide therapy hitting the tumor and saving the kidney. Eur J Nucl Med. 2001;28:1447-1449.
46. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy yttrium 90-DOTATOC internal radiotherapy Am J Kidney Dis. 2001;37:847-851.
47. Cohen EP, Moulder JE, Robbins ME. Radiation nephropathy caused by yttrium 90. Lancet. 2001;358:1102-1103.
48. Breitz H, Wendt R, Stabin M, Bouchet L, Wessels B. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166-Ho-DOTMP. Cancer Biother Radiopharm 2003;18:225-230
49. O'Donoghue JA Optimal therapeutic strategies for radioimmunotherapy. Recent Results Cancer Res. 1996;141:77-99
50. O'Donoghue JA, Sgouros G, Divgi CR, Humm JL Single-dose versus fractionated radioimmunotherapy, model comparisons for uniform tumor dosimetry. J Nucl Med. 2000;41:538-547
51. Thames HD, Hendry JH. Fractionation in Radiotherapy. London, U.K.: Taylor and Francis; 1987